EM
GSK icon

Excalibur Management’s GSK GSK Stock Holding History

Excalibur Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Sell
11,594
-94
-0.8% -$4.97K 0.2% 97
2026
Q1 		$645K Sell
11,688
-400
-3% -$21.7K 0.23% 93
2025
Q4 		$593K Sell
12,088
-40
-0.3% -$1.87K 0.21% 98
2025
Q3 		$523K Sell
12,128
-126
-1% -$4.92K 0.19% 104
2025
Q2 		$471K Sell
12,254
-122
-1% -$4.66K 0.18% 106
2025
Q1 		$479K Buy
12,376
+195
+2% +$7.14K 0.19% 102
2024
Q4 		$412K Sell
12,181
-328
-3% -$11.8K 0.16% 111
2024
Q3 		$511K Sell
12,509
-252
-2% -$10.3K 0.2% 99
2024
Q2 		$491K Buy
12,761
+130
+1% +$5.47K 0.2% 99
2024
Q1 		$541K Buy
12,631
+100
+0.8% +$4.12K 0.23% 93
2023
Q4 		$468K Sell
12,531
-119
-0.9% -$4.27K 0.22% 95
2023
Q3 		$459K Sell
12,650
-60
-0.5% -$2.13K 0.24% 95
2023
Q2 		$453K Sell
12,710
-480
-4% -$17.2K 0.23% 94
2023
Q1 		$469K Buy
13,190
+90
+0.7% +$3.15K 0.24% 93
2022
Q4 		$460K Sell
13,100
-48
-0.4% -$1.6K 0.24% 96
2022
Q3 		$387K Buy
13,148
+2,302
+21% +$87.2K 0.22% 96
2022
Q2 		$590K Sell
10,846
-240
-2% -$13.2K 0.31% 76
2022
Q1 		$604K Sell
11,086
-14
-0.1% -$760 0.26% 82
2021
Q4 		$612K Sell
11,100
-234
-2% -$12.2K 0.25% 92
2021
Q3 		$541K Buy
11,334
+224
+2% +$11.3K 0.24% 93
2021
Q2 		$553K Buy
11,110
+260
+2% +$12.5K 0.25% 88
2021
Q1 		$484K Buy
10,850
+3,632
+50% +$165K 0.24% 88
2020
Q4 		$332K Buy
7,218
+510
+8% +$23.4K 0.18% 108
2020
Q3 		$316K Buy
6,708
+504
+8% +$25.3K 0.19% 97
2020
Q2 		$316K Buy
6,204
+256
+4% +$13.1K 0.21% 84
2020
Q1 		$282K Sell
5,948
-112
-2% -$5.97K 0.22% 83
2019
Q4 		$356K Buy
+6,060
New +$337K 0.23% 76

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Excalibur Management's GSK Position: Q2 2026 in Review

Excalibur Management reduced its GSK (GSK) stake by 0.8% in Q2 2026, selling an estimated $4.97K and leaving 11,594 shares worth $608K. The position accounts for 0.2% of the portfolio, ranked #97.

Excalibur Management first reported a position in GSK in Q4 2019 and has held it in 27 quarters since. The position peaked at $645K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Excalibur Management held 11,594 shares of GSK worth $608K as of Q2 2026.
  • Excalibur Management sold 94 GSK shares in Q2 2026, an estimated $4.97K.
  • GSK made up 0.2% of Excalibur Management's portfolio in Q2 2026, its #97 holding.
  • Excalibur Management first reported a position in GSK in Q4 2019 and has held it in 27 quarters since.
  • Excalibur Management's GSK position peaked at $645K in Q1 2026.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Excalibur Management's 13F filing for Q2 2026, filed 3 Aug 2026.